Company
Egetis Therapeutics AB
Headquarters: Stockholm, Sweden
Employees: 12
Market Cap
€146.4 Million
EUR as of Jan. 1, 2024
US$161.7 Million
Egetis Therapeutics AB Categories
Sweden Healthcare BiotechnologySweden Healthcare Sweden Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Egetis Therapeutics AB has the following listings and related stock indices.
Stock: FSX: P0F wb_incandescent